However, as shown in Figure 4, after sequential third-generation EGFR-TKI treatment, the univariate analysis yielded that pericardial effusion (p = 0.028), paclitaxel history (p = 0.029), and lower serum potassium level (p = 0.032) were risk factors for additional top-QTc prolongation after sequential third-generation EGFR-TKI treatment. The gene discussed is EGFR; the disease is pericardial effusion.